Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus.

@article{Witcher2016PharmacokineticsAS,
  title={Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus.},
  author={Jennifer W. Witcher and Roy M Fleischmann and Vishala L Chindalore and Ryan John Hansen and Leijun Hu and David B. Radtke and James R. Voelker and Elisa V. Gomez and Juliet McColm},
  journal={British journal of clinical pharmacology},
  year={2016},
  volume={81 5},
  pages={
          908-17
        }
}
AIMS Two phase 1 studies evaluated the pharmacokinetics (PK), safety and biological activity of tabalumab, a human monoclonal antibody against B-cell activating factor (BAFF), administered intravenously (i.v.) or subcutaneously (s.c.) in subjects with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). METHODS In study A, subjects with RA (n = 23) or SLE (n = 6) received a single i.v. dose of tabalumab (RA 0.01, 0.04, 0.125, 0.5, 2.0, and 8.0 mg kg(-1) and SLE 0.125 or 2.0 mg kg… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES

Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies

Z Fattah, DA Isenberg
  • Expert Opin Biol Ther
  • 2014

Population pharmacokinetic modeling of sparse data of tabalumab in phase II studies of rheumatoid arthritis patients using a Bayesian approach (T-031)

Y Ji, D Radtke, J Satterwhite, PY. Berclaz
  • J Pharmacokinet Pharmacodyn
  • 2013